CLAIM #36547 · Eli Lilly and Company (LLY) · 2022Q1 earnings call · Apr 28, 2022 · due Dec 31, 2022
“We are looking forward to further data from our maintenance studies in the first half of this year to provide insight into the durability of efficacy. Global submissions are expected by year end.”
Dr. Dan Skovronsky · CSO
PENDING
graded after results covering Dec 31, 2022 are reported
Verify independently
SEC filings for LLY ↗ · Claim quote is verbatim from the 2022Q1 earnings call.